TPX2 and neoplasm: On the other hand, the observation that high levels of AurkA and TPX2 are associated with taxane-based radiosensitisation [98], a strategy currently used in clinical protocols for a large spectrum of tumours, suggests that their involvement in therapeutic responses may depend on tumour or treatment specificity, highlighting the need for further investigation.